A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

Autor: Rawstron, AC, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, K-A, Liptrot, S, O'Brien, D, de Tute, RM, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, AP, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, JL, Stetler-Stevenson, M, Yuan, C, Broome, HE, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, CM, Emerson, R, Robins, HS, Kirsch, I, Shanafelt, T, Pettitt, A, Kipps, TJ, Wierda, WG, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, P, CLL, ERIC European Res Initiative
Přispěvatelé: Rawstron, Ac, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, Ka, Liptrot, S, O'Brien, D, de Tute, Rm, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, Ap, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, Jl, Stetler Stevenson, M, Yuan, C, Broome, He, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, Cm, Emerson, R, Robins, H, Kirsch, I, Shanafelt, T, Pettitt, A, Kipps, Tj, Wierda, Wg, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, PAOLO PROSPERO, AII - Amsterdam institute for Infection and Immunity, CCA -Cancer Center Amsterdam, Clinical Haematology
Jazyk: angličtina
Rok vydání: 2016
Předmět:
0301 basic medicine
Oncology
Male
Cancer Research
Neoplasm
Residual
Lymphoma
Chronic lymphocytic leukemia
0302 clinical medicine
Immunophenotyping
immune system diseases
hemic and lymphatic diseases
Chronic
Cancer
CD20
Hematology
Leukemia
biology
High-Throughput Nucleotide Sequencing
Prognosis
Flow Cytometry
Combined Modality Therapy
Lymphocytic
3. Good health
CD
Europe
030220 oncology & carcinogenesis
Residual
Original Article
Female
Adult
medicine.medical_specialty
Adolescent
Clinical Sciences
Oncology and Carcinogenesis
Immunology
03 medical and health sciences
Young Adult
Rare Diseases
Antigens
CD
Internal medicine
medicine
Humans
Antigens
Neoplasm Staging
business.industry
B-Cell
CD79B
medicine.disease
Leukemia
Lymphocytic
Chronic
B-Cell
Minimal residual disease
Orphan Drug
030104 developmental biology
biology.protein
Neoplasm
CD5
business
Follow-Up Studies
Zdroj: Leukemia
Leukemia, vol 30, iss 4
Leukemia, 30(4), 929-936. Nature Publishing Group
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
ISSN: 0887-6924
Popis: In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay comprises a core panel of six markers (i.e. CD19, CD20, CD5, CD43, CD79b and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood. This method is directly comparable to previous ERIC-designed assays and also provides a backbone for investigation of new markers. A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.
Databáze: OpenAIRE
Externí odkaz: